Abbott Labs (ABT)

Abbott announced that it has completed its acquisition of Evalve, Inc., the global leader in the development of devices for minimally invasive repair of mitral valves.
The acquisition provides Abbott with a leading presence in the growing area of non-surgical treatment for structural heart disease. Evalve's minimally invasive catheter-based MitraClip® system is the first commercially available treatment option approved in Europe for non-surgical mitral valve repair for patients suffering from the effects of mitral regurgitation, a condition that prevents the heart's mitral valve from closing completely.

Nov 3 · 11:43:00 AM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto